Pressure BioSciences, Inc. to Present at the 2010 OneMedForum-New York Finance Conference
SOUTH EASTON, Mass., June 30, 2010 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI") today announced that it will present at the 2010 OneMedForum-New York Finance Conference at 11am on Wednesday, June 30, 2010. The conference is being held at the Roosevelt Hotel in New York City. Mr. Richard T. Schumacher, PBI President and CEO, will provide a corporate overview. A live web cast will be available at http://www.onemedplace.com/forum/webcast.php. The web cast link will be available on June 30th, and will remain live for 90 days following the conference.
.About the 2010 OneMedForum Finance Conference
The OneMedForum has broadened its reach to the East Coast-New York with its inaugural finance forum following the success of its annual conference held in San Francisco each January. The 2010 OneMedForum finance conference connects emerging healthcare and life science companies with investors and strategic partners. There will be over 75 company presentations by some of the most promising, and typically least recognized companies in the world. For more information, please visit www.onemedplace.com/onemedforum/.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
CONTACT: Pressure BioSciences, Inc. Investor Contacts: Richard T. Schumacher, President & CEO R. Wayne Fritzsche, Chairman (508) 230-1828
Released June 30, 2010